MarketCap
Facebook
X
TelegramQuarterly report 2022-Q3
added 11-14-2022
Opiant Pharmaceuticals ROE Ratio 2011-2026 | OPNT
Annual ROE Ratio Opiant Pharmaceuticals
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 6.42 | -5.24 | 33.69 | -125.72 | 151.82 | 166.09 | 83.92 | 373.05 | 470.24 | 15.28 | 2787.39 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2787.39 | -125.72 | 359.72 |
Quarterly ROE Ratio Opiant Pharmaceuticals
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -119.07 | -110.93 | -54.43 | -10.14 | 4.4 | 6.44 | 0.35 | -4.89 | -3.31 | 27.73 | 56.73 | 61.92 | 30.58 | 25.14 | -11.35 | -24.22 | -69.15 | 12.77 | -8.01 | 2.11 | 14.2 | -148.68 | -110.72 | 39.19 | 95.29 | 222.51 | 331.31 | 221.89 | 341.6 | 592.37 | 493.18 | 670.75 | 563.47 | 878.68 | 950.42 | 1452.46 | 1600.39 | 2538.05 | 2547.16 | 3327.88 | 3331.9 | 3821.44 | 5758.72 | 7043.44 | 6221.19 | 2039.46 | 2787.39 | 1394.35 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 7043.44 | -148.68 | 1017.33 |
ROE Ratio of other stocks in the Biotechnology industry
| Issuer | ROE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Acorda Therapeutics
ACOR
|
160.08 | - | -24.86 % | $ 820 K |  USA |
 |
Adverum Biotechnologies
ADVM
|
-185.15 | - | - | $ 86.2 M | USA |
 |
MorphoSys AG
MOR
|
15.76 | - | 2.43 % | $ 254 M |  Germany |
 |
Alterity Therapeutics Limited
ATHE
|
-36.22 | $ 3.73 | - | $ 8.97 B |  Australia |
 |
Akouos
AKUS
|
-37.09 | - | 0.23 % | $ 488 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
39.76 | $ 333.39 | - | $ 43.7 B | USA |
 |
Applied Molecular Transport
AMTI
|
-207.64 | - | - | $ 10.1 M | USA |
 |
I-Mab
IMAB
|
-85.31 | - | - | $ 866 M |  China |
 |
AlloVir
ALVR
|
-55.11 | - | 4.14 % | $ 49.1 M | USA |
 |
Burford Capital Limited
BUR
|
10.1 | $ 4.73 | - | $ 784 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.18 | - | - | $ 40.3 B | USA |
 |
Cabaletta Bio
CABA
|
-149.8 | $ 3.4 | - | $ 342 M | USA |
 |
Genfit SA
GNFT
|
626.29 | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-751.94 | - | -13.47 % | $ 169 M | France |
 |
Aligos Therapeutics
ALGS
|
-45.18 | $ 7.42 | - | $ 73.3 M | USA |
 |
Allakos
ALLK
|
-110.0 | - | - | $ 28.6 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-175.75 | $ 3.17 | - | $ 5.22 M |  Israel |
 |
Ayala Pharmaceuticals
AYLA
|
3458.87 | - | - | $ 7.46 M | Israel |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-115.61 | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
-330.29 | - | -18.52 % | $ 27.3 M | Britain |
 |
Applied Therapeutics
APLT
|
698.49 | - | - | $ 8.42 M | USA |
 |
Aptinyx
APTX
|
-169.38 | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
-716.17 | - | -13.39 % | $ 1.45 M | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
103.22 | - | -2.5 % | $ 5.88 M | USA |
 |
CNS Pharmaceuticals
CNSP
|
-350.48 | $ 2.75 | 4.16 % | $ 1.22 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
12.44 | $ 21.68 | - | $ 1.01 B | USA |
 |
CymaBay Therapeutics
CBAY
|
-36.05 | - | - | $ 3.45 B | USA |
 |
BioNTech SE
BNTX
|
1.11 | $ 99.47 | - | $ 27.2 B | Germany |
 |
Институт стволовых клеток человека
ISKJ
|
17.55 | - | - | - |  Russia |
 |
Advaxis
ADXS
|
196.88 | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
-401.79 | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
51843.24 | - | -10.17 % | $ 12.2 K | USA |
 |
ContraFect Corporation
CFRX
|
549.72 | - | -5.16 % | $ 5.39 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-21.7 | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
-16.39 | $ 1.55 | - | $ 399 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-62.37 | - | - | $ 26.5 M | USA |
 |
Aquestive Therapeutics
AQST
|
248.9 | $ 4.24 | - | $ 453 M | USA |
 |
Galectin Therapeutics
GALT
|
24.11 | $ 2.56 | - | $ 164 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-8.52 | $ 24.58 | - | $ 3.13 B | USA |
 |
AIkido Pharma
AIKI
|
-32.34 | - | 1.93 % | $ 17.4 M | USA |
 |
BioDelivery Sciences International
BDSI
|
45.18 | - | -4.8 % | $ 255 M | USA |
 |
Genmab A/S
GMAB
|
24.88 | $ 29.3 | - | $ 18.8 B |  Danmark |
 |
Autolus Therapeutics plc
AUTL
|
-161.42 | $ 1.49 | - | $ 397 M | Britain |
 |
Aptose Biosciences
APTO
|
93.75 | - | -45.71 % | $ 1.2 M | Canada |
 |
BeiGene, Ltd.
BGNE
|
6.58 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Checkpoint Therapeutics
CKPT
|
445.47 | - | - | $ 169 M | USA |
 |
Caladrius Biosciences
CLBS
|
-67.58 | - | -16.75 % | $ 25.8 M | USA |
 |
Celldex Therapeutics
CLDX
|
-49.08 | $ 33.87 | - | $ 2.25 B | USA |
 |
AVROBIO
AVRO
|
12.83 | - | 1083.1 % | $ 745 M | USA |
 |
Clearside Biomedical
CLSD
|
204.15 | - | - | $ 25.3 M | USA |